These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 20881644

  • 1. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [Abstract] [Full Text] [Related]

  • 2. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, Cha SI, Yoon GS, Kim CH, Jung TH, Park JY.
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [Abstract] [Full Text] [Related]

  • 3. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 4. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
    Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R.
    Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H.
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [Abstract] [Full Text] [Related]

  • 7. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, Sun Y, Chen H.
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [Abstract] [Full Text] [Related]

  • 8. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
    Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MA, Vidigal PV, Vilhena A, Amaral NF, Bale AE, Friedman E, De Marco L.
    Genet Res (Camb); 2014 Jun; 96():e002. PubMed ID: 24594201
    [Abstract] [Full Text] [Related]

  • 9. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
    Bhaumik S, Ahmad F, Das BR.
    Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
    [Abstract] [Full Text] [Related]

  • 10. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, Sun Y, Chen H.
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [Abstract] [Full Text] [Related]

  • 11. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
    Zhang H, Liu D, Li S, Zheng Y, Yang X, Li X, Zhang Q, Qin N, Lu J, Ren-Heidenreich L, Yang H, Wu Y, Zhang X, Nong J, Sun Y, Zhang S.
    J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.
    Cancer; 2015 Feb 01; 121(3):448-56. PubMed ID: 25273224
    [Abstract] [Full Text] [Related]

  • 13. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.
    Anticancer Res; 2013 Apr 01; 33(4):1705-11. PubMed ID: 23564819
    [Abstract] [Full Text] [Related]

  • 14. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.
    J Thorac Oncol; 2009 Jan 01; 4(1):12-21. PubMed ID: 19096301
    [Abstract] [Full Text] [Related]

  • 15. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.
    Hum Pathol; 2014 Dec 01; 45(12):2379-87. PubMed ID: 25288236
    [Abstract] [Full Text] [Related]

  • 16. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF, Chen XY, Yu XB.
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr 08; 45(4):221-5. PubMed ID: 27033383
    [Abstract] [Full Text] [Related]

  • 17. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.
    Cancer; 2012 Feb 01; 118(3):729-39. PubMed ID: 21720997
    [Abstract] [Full Text] [Related]

  • 18. Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips.
    Emelyanova M, Arkhipova K, Mazurenko N, Chudinov A, Demidova I, Zborovskaya I, Lyubchenko L, Zasedatelev A, Nasedkina T.
    Appl Immunohistochem Mol Morphol; 2015 Apr 01; 23(4):255-65. PubMed ID: 25153497
    [Abstract] [Full Text] [Related]

  • 19. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S, Shuai Y, Cieply K, Nikiforova MN, Dacic S.
    Hum Pathol; 2010 Aug 01; 41(8):1053-60. PubMed ID: 20381121
    [Abstract] [Full Text] [Related]

  • 20. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2012 Oct 01; 7(10):1513-21. PubMed ID: 22982652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.